Status:
COMPLETED
Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer
Lead Sponsor:
Pfizer
Conditions:
Breast Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This study is to evaluate the safety of SU011248 in combination with paclitaxel in patients with metastatic or locally recurrent breast cancer who have not received chemotherapy treatment in the advan...
Eligibility Criteria
Inclusion
- Breast cancer with evidence of unresectable, locally recurrent or metastatic disease.
- Candidate for treatment with paclitaxel.
Exclusion
- Prior chemotherapy in the advanced disease setting.
- HER2 positive disease unless previously treated with trastuzumab.
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2007
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT00174434
Start Date
September 1 2005
End Date
August 1 2007
Last Update
January 27 2009
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Harvey, Illinois, United States, 60426-4265
2
Pfizer Investigational Site
Harvey, Illinois, United States, 60426
3
Pfizer Investigational Site
Indianapolis, Indiana, United States, 46202
4
Pfizer Investigational Site
Indianapolis, Indiana, United States, 46290